Hikma Pharmaceuticals PLC
Research Hikma Pharmaceuticals PLC (HIK) on Bullrun: market cap GBX 322.66B, P/E 11.2, dividend yield 4.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHIK
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyGBX
- Market capGBX 322.66B
- P/E11.2
- Dividend yield4.0%
- Financial periodFY2025
- RevenueGBP 3.35B
- Revenue growth7.1%
- Net incomeGBP 402.00M
- Free cash flowGBP 119.00M
- Gross margin43.0%
Valuation Snapshot
latest market cap is GBX 322.66B; P/E is 11.2; dividend yield is 4.0%.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
Frequently asked questions
What is Hikma Pharmaceuticals PLC's market cap?
Hikma Pharmaceuticals PLC's market capitalization is GBX 322.66B.
What is Hikma Pharmaceuticals PLC's P/E ratio?
Hikma Pharmaceuticals PLC's price-to-earnings (P/E) ratio is 11.2.
Does Hikma Pharmaceuticals PLC pay a dividend?
Hikma Pharmaceuticals PLC has a dividend yield of 4.0%.
What does Hikma Pharmaceuticals PLC do?
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded.